Overview

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Status:
Completed

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find biological response patterns of patients with rheumatoid arthritis to drugs with different biologic modes of action. This study should help to predict therapeutic responses and to find the right therapy for the right patient.

Phase:

Phase 4

Details

Lead Sponsor:

Medical University of Vienna

Treatments:

Abatacept
Diphenhydramine
Infliximab
Promethazine
Rituximab